SCHEMBL13479744

SCHEMBL13479744

Cc1cc(C)c2c(=O)cc(-c3ccc(C)c(C)c3)oc2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK2A2 P19784 4/20 0.64
▸ CSNK2B P67870 4/20 0.64
▸ CSNK2A1 P68400 4/20 0.64
▸ ADORA3 P0DMS8 2/20 0.55
▸ MAPT P10636 5/20 0.51
▸ TP53 P04637 3/20 0.51
▸ CYP3A4 P08684 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ PARP1 P09874 3/20 0.49
▸ PARP2 Q9UGN5 2/20 0.49
▸ AR P10275 1/20 0.47
▸ QPCT Q16769 1/20 0.46
▸ CCNC P24863 1/20 0.45
▸ CDK8 P49336 1/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ ABCB1 P08183 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ ABCG2 Q9UNQ0 2/20 0.44
▸ MDM2 Q00987 1/20 0.44
▸ TNKS O95271 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28568538 0.83 CYP3A4 (0.72) CSNK2A2CSNK2BCSNK2A1ADORA3MAPT
SCHEMBL20664412 0.81 ADORA3 (0.76) CSNK2A2CSNK2BCSNK2A1ADORA3MAPT
SCHEMBL28914421 0.80 GABRP (0.57) CSNK2A2CSNK2BCSNK2A1ADORA3MAPT
SCHEMBL28925280 0.78 ADORA3 (0.50) CSNK2A2CSNK2BCSNK2A1ADORA3MAPT
SCHEMBL20718935 0.77 ABCB1 (0.71) CSNK2A2CSNK2BCSNK2A1ADORA3MAPT
SCHEMBL28588026 0.77 CYP3A4 (0.62) CSNK2A2CSNK2BCSNK2A1ADORA3MAPT
SCHEMBL28576015 0.77 CSNK2A2 (0.53) CSNK2A2CSNK2BCSNK2A1ADORA3MAPT
SCHEMBL24046787 0.77 CSNK2A2 (0.53) CSNK2A2CSNK2BCSNK2A1ADORA3MAPT
SCHEMBL13598259 0.76 CSNK2A2 (0.51) CSNK2A2CSNK2BCSNK2A1ADORA3MAPT
SCHEMBL25734128 0.75 POLH (0.49) CSNK2A2CSNK2BCSNK2A1ADORA3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100028400-A1 PHARMACEUTICAL COMPOSITION ON THE BASIS OF STACHYTARPHETA SP., A PROCESS FOR OBTAINING THE SAME AND ITS USE FOR TREATING VITILIGO ACHE LABORATORIOS FARMACEUTICOS S/A (BR) 2010-02-04 — — US disclosed
US-20080045478-A1 For skin/hair light protection; cosmetics MERCK PATENT GMBH (DE) 2008-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100028400-A1 PHARMACEUTICAL COMPOSITION ON THE BASIS OF STACHYTARPHETA SP., A PROCESS FOR OBTAINING THE SAME AND ITS USE FOR TREATING VITILIGO LSS, LCT, VPS35 CSNK2A2 2012/4885CSNK2B 1764/4885CSNK2A1 1847/4885
US-20080045478-A1 For skin/hair light protection; cosmetics CUTA, TYR, COXFA4L2 CSNK2A2 3963/4885CSNK2B 3710/4885CSNK2A1 4054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback